Drug and Therapeutics Bulletin 2008;46:1-3; doi:10.1136/dtb.2007.12.0006
Copyright © 2008 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Eplerenone after myocardial infarction?

Relevant BNF section: 2.2.3

Each year in the UK, an estimated 50,000 patients develop major left ventricular systolic dysfunction (LVSD) and heart failure following a myocardial infarct.1 Such patients have a particularly poor prognosis.2 {blacktriangledown}Eplerenone (Inspra – Pfizer) is an aldosterone-receptor antagonist for patients who have LVSD and heart failure following a recent myocardial infarct. Here, we discuss whether such patients should receive this drug.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2008 BMJ Publishing Group Ltd.